Hyloris reported FY25 results with a cash position of € 13.8m (YE24: € 23.6m), and revenue of € 7.2m (FY24: € 8.5m), driven by increased royalties but offset by lower milestone payments. Hyloris is yet to receive income related to commercialisation of Maxigesic IV in the US as the launch has been paused and restarted. The company did not provide specific cash runway guidance, but believes it has funding for development and strategic growth. € 6 TP and Hold maintained.
Galapagos announced that, following Gilead entering into a definitive agreement to acquire Ouro Medicines for $1,675m in cash consideration, and up to $500m in contingent milestone payments, Galapagos and Gilead are in advanced partnership discussions. Economically, Galapagos would effectively co-finance Gilead's acquisition and early-stage development of gamgertamig in return for royalties on net sales (20-23%) and freedom to go up to $500m (previously $150m) in the amended OLCA. In our view, t...
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities Mechelen, Belgium; March 23, 2026, 23:02 CE...
Galapagos en Gilead in vergevorderde gesprekken over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen Galapagos is van plan een strategische samenwerking aan te gaan met Gilead, na de overname van Ouro Medicines door Gilead De nieuwe partnerstructuur zou aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos opleveren Na deze potentiële transactie zal de Vennootschap het grootste deel van haar kapitaal beschikbaar blijven houden voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocat...
Disclosure of a transparency notification from Aberdeen Group plc Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Aberdeen Group plc, dated 16 March 2026. Notification from Aberdeen Group plc On 19 March 2026, Fagron received a transparency notification from Aberdeen Group plc, informing the Company that its shareholding has...
Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 20 maart 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van Aberdeen Group plc Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, gedateerd op 16 maart 2026. Kennisgeving van Aberdeen Group plc Op 19 maart 2026 ontving Fagron een transparantiekennisgeving van Aberdeen Group plc, waarin aan...
Our analysis of U.S. compounding capacity and utilization shows that North America can sustain double-digit organic growth, driving our 7.4% organic revenue CAGR (25–30) for the group. We expect strong REBITDA growth in 2026, and margin decrease due to acquisitions. Long-term margin upside is well supported by the new U.S. facilities and improved efficiency through centralized manufacturing and vertical integration in LatAm. The market continues to undervalue Fagron by focusing too heavily on ma...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.